JP2012153722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012153722A5 JP2012153722A5 JP2012112647A JP2012112647A JP2012153722A5 JP 2012153722 A5 JP2012153722 A5 JP 2012153722A5 JP 2012112647 A JP2012112647 A JP 2012112647A JP 2012112647 A JP2012112647 A JP 2012112647A JP 2012153722 A5 JP2012153722 A5 JP 2012153722A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- use according
- pharmaceutical formulation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IBXPYPUJPLLOIN-UHFFFAOYSA-N Cc([n]1C)ncc1[N+]([O-])=O Chemical compound Cc([n]1C)ncc1[N+]([O-])=O IBXPYPUJPLLOIN-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1ccc(*)[s]1 Chemical compound Cc1ccc(*)[s]1 0.000 description 1
- FNEJQOIAGPBETK-UHFFFAOYSA-N Cc1ccc(O)[o]1 Chemical compound Cc1ccc(O)[o]1 FNEJQOIAGPBETK-UHFFFAOYSA-N 0.000 description 1
- HLEIGKIQLNEZMS-UHFFFAOYSA-N Cc1cnc(N)[n]1C Chemical compound Cc1cnc(N)[n]1C HLEIGKIQLNEZMS-UHFFFAOYSA-N 0.000 description 1
Claims (33)
- 以下の式:
Lは、CH 2 、CHMe、CMe 2 、
Z 3 は、以下:
各R 9 は、独立して、水素、アリール、ヘテロアリール、C 1 −C 4 アルキル、C 1 −C 6 へテロアルキル、C 3 −C 8 シクロアルキル、ヘテロシクリル、C 1 −C 6 アシル、C 1 −C 6 ヘテロアシル、アロイル、ヘテロアロイル、C 1 −C 6 アルコキシカルボニル、C 1 −C 6 アルキルアミノカルボニル、ジC 1 −C 6 アルキルアミノカルボニルおよびC 1 −C 6 アルコキシからなる群より選択され;
各X 4 は、ハロ、アルキルスルホニルオキシ、ヘテロアルキルスルホニルオキシ、シクロアルキルスルホニルオキシ、ヘテロシクリルスルホニルオキシ、アリールスルホニルオキシおよびヘテロアリールスルホニルオキシからなる群より選択される、
化合物またはその薬学的に受容可能な塩。 - 請求項1〜4のいずれか1項に記載の化合物またはその薬学的に受容可能な塩と、薬学的に受容可能な賦形剤、キャリアまたは希釈剤とを含む、薬学的処方物。
- 前記希釈剤が水、エタノール、プロピレングリコール、グリセリンまたはこれらの組み合わせである、請求項5に記載の薬学的処方物。
- 癌を治療するための薬学的処方物の製造のための、請求項1に記載の化合物の使用。
- 前記癌が、固形腫瘍癌、軟部組織肉腫、白血病、多発性骨髄腫、前立腺癌、膵臓癌、乳癌、肺癌、結腸直腸癌、頭頸部癌、卵巣癌、脳の癌、星状細胞腫および腎細胞腫瘍からなる群より選択される、請求項8に記載の使用。
- 前記処方物が別の抗癌剤と組み合わせて投与されることを特徴とする、請求項8に記載の使用。
- 前記処方物がダウノルビシンまたはシスプラチンと組み合わせて投与されることを特徴とする、請求項11に記載の使用。
- 前記処方物がダウノルビシン、パクリタキセルまたはシスプラチンと組み合わせて投与されることを特徴とする、請求項13に記載の使用。
- 前記処方物がゲムシタビンと組み合わせて投与されることを特徴とする、請求項15に記載の使用。
- 前記化合物が、一回投与または分割投与で、0.001〜0.1g/kg/日の投与量で使用される、請求項8に記載の使用。
- 前記化合物が、一回投与または分割投与で、0.1〜35mg/kg/日の投与量で使用される、請求項8に記載の使用。
- 前記化合物が、一回投与または分割投与で、0.5〜15mg/kg/日の投与量で使用される、請求項8に記載の使用。
- 請求項1に記載の化合物を含む、癌を治療するための薬学的処方物。
- 前記癌が、固形腫瘍癌、軟部組織肉腫、白血病、多発性骨髄腫、前立腺癌、膵臓癌、乳癌、肺癌、結腸直腸癌、頭頸部癌、卵巣癌、脳の癌、星状細胞腫および腎細胞腫瘍からなる群より選択される、請求項25に記載の薬学的処方物。
- 別の抗癌剤と組み合わせて投与されることを特徴とする、請求項25に記載の薬学的処方物。
- ダウノルビシンまたはシスプラチンと組み合わせて投与されることを特徴とする、請求項25に記載の薬学的処方物。
- ダウノルビシン、パクリタキセルまたはシスプラチンと組み合わせて投与されることを特徴とする、請求項25に記載の薬学的処方物。
- ゲムシタビンと組み合わせて投与されることを特徴とする、請求項25に記載の薬学的処方物。
- 前記化合物が、一回投与または分割投与で、0.001〜0.1g/kg/日の投与量で使用される、請求項25に記載の薬学的処方物。
- 前記化合物が、一回投与または分割投与で、0.1〜35mg/kg/日の投与量で使用される、請求項25に記載の薬学的処方物。
- 前記化合物が、一回投与または分割投与で、0.5〜15mg/kg/日の投与量で使用される、請求項25に記載の薬学的処方物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69575505P | 2005-06-29 | 2005-06-29 | |
US60/695,755 | 2005-06-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519666A Division JP5180824B2 (ja) | 2005-06-29 | 2006-06-29 | ホスホルアミデートアルキル化剤プロドラッグ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012153722A JP2012153722A (ja) | 2012-08-16 |
JP2012153722A5 true JP2012153722A5 (ja) | 2013-02-07 |
JP5781007B2 JP5781007B2 (ja) | 2015-09-16 |
Family
ID=37596083
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519666A Active JP5180824B2 (ja) | 2005-06-29 | 2006-06-29 | ホスホルアミデートアルキル化剤プロドラッグ |
JP2012112647A Active JP5781007B2 (ja) | 2005-06-29 | 2012-05-16 | ホスホルアミデートアルキル化剤プロドラッグ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519666A Active JP5180824B2 (ja) | 2005-06-29 | 2006-06-29 | ホスホルアミデートアルキル化剤プロドラッグ |
Country Status (24)
Country | Link |
---|---|
US (4) | US8003625B2 (ja) |
EP (2) | EP1896040B1 (ja) |
JP (2) | JP5180824B2 (ja) |
KR (1) | KR101198571B1 (ja) |
CN (2) | CN102746336B (ja) |
AU (2) | AU2006263433B8 (ja) |
BR (1) | BRPI0612845A8 (ja) |
CA (1) | CA2613312C (ja) |
CY (1) | CY1113250T1 (ja) |
DK (1) | DK1896040T3 (ja) |
ES (2) | ES2579235T3 (ja) |
HK (1) | HK1113754A1 (ja) |
HR (1) | HRP20120803T1 (ja) |
IL (1) | IL188236A (ja) |
NO (1) | NO334420B1 (ja) |
NZ (1) | NZ565378A (ja) |
PL (1) | PL1896040T3 (ja) |
PT (1) | PT1896040E (ja) |
RS (1) | RS52505B (ja) |
RU (1) | RU2414475C2 (ja) |
SI (1) | SI1896040T1 (ja) |
TW (1) | TWI384989B (ja) |
WO (1) | WO2007002931A2 (ja) |
ZA (1) | ZA200800314B (ja) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1896040T3 (pl) * | 2005-06-29 | 2012-12-31 | Threshold Pharmaceuticals Inc | Proleki alkilatora fosforoamidowego |
US8552048B2 (en) * | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
US8765690B2 (en) | 2007-04-05 | 2014-07-01 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with glufosfamide in patients not receiving insulin therapy |
WO2009018163A1 (en) * | 2007-07-27 | 2009-02-05 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of anthracyclines |
UA104579C2 (uk) | 2007-12-10 | 2014-02-25 | Байокрист Фармасьютикалз, Инк. | Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом |
CN102256966B (zh) | 2008-10-17 | 2016-02-10 | 白头生物医学研究所 | 可溶性mTOR复合物和其调节剂 |
US8946275B2 (en) * | 2008-10-21 | 2015-02-03 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
WO2012006032A2 (en) * | 2010-06-28 | 2012-01-12 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
US20140010805A1 (en) * | 2010-07-12 | 2014-01-09 | Karen Curd | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
KR20140038390A (ko) * | 2011-04-01 | 2014-03-28 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
JP2014510795A (ja) * | 2011-04-15 | 2014-05-01 | スレッショルド ファーマシューティカルズ、インク. | 経口投与用の単位用量形態物 |
US9402820B2 (en) * | 2011-04-22 | 2016-08-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors |
CN102850397B (zh) * | 2011-06-29 | 2015-02-18 | 北京大学 | 多靶点抗肿瘤化合物及其制备方法和应用 |
CN102924507A (zh) * | 2011-11-10 | 2013-02-13 | 安徽四维药业有限公司 | 一种抗肿瘤化合物及其制备方法与应用、药物组合物 |
EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA ACTIVATED DRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
EP2793899A4 (en) * | 2011-12-22 | 2015-06-17 | Threshold Pharmaceuticals Inc | HYPOXIA ACTIVATED DRUGS AND MTOR INHIBITORS FOR TREATING CANCER |
ES2909741T3 (es) * | 2012-02-21 | 2022-05-10 | Immunogenesis Inc | Tratamiento del cáncer |
WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
US20150183818A1 (en) * | 2012-07-03 | 2015-07-02 | Bristol-Myers Squibb Company | Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections |
WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
JP5922791B2 (ja) | 2012-10-29 | 2016-05-24 | 京セラ株式会社 | 弾性表面波センサ |
WO2015013448A1 (en) | 2013-07-26 | 2015-01-29 | Threshold Pharmaceuticals, Inc. | Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane |
WO2015025283A2 (en) | 2013-08-20 | 2015-02-26 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Dual action carbonic anhydrase inhibitors |
US20160251387A1 (en) | 2013-10-10 | 2016-09-01 | Merck Patent Gmbh | Synthesis of 1-alkyl-2-amino-imidazol-5-carboxylic acid ester via calpha-substituted n-alkyl-glycine ester derivatives |
WO2015069489A1 (en) | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
CN104628772A (zh) * | 2013-11-07 | 2015-05-20 | 四川恒康发展有限责任公司 | 一种抗肿瘤前药及其激活剂、组合物和应用 |
US10449210B2 (en) * | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
US10131683B2 (en) | 2014-07-17 | 2018-11-20 | Molecular Templates, Inc. | TH-302 solid forms and methods related thereto |
EP3747508B1 (en) * | 2015-03-10 | 2021-10-13 | Ascenta Pharmaceuticals, Ltd. | Dna alkylating agents for use in the treatment of cancer |
SG11201707375UA (en) | 2015-04-02 | 2017-10-30 | Ascenta Pharmaceuticals Ltd | Nitrobenzyl derivatives of anti-cancer agents |
CN105037427B (zh) * | 2015-06-22 | 2017-05-31 | 石家庄学院 | 丹参酮iia亚乙基亚胺磷酸酯衍生物及其制备方法与应用 |
PL412787A1 (pl) | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
CA2990665A1 (en) * | 2015-06-24 | 2016-12-29 | Threshold Pharmaceuticals, Inc. | Aziridine containing dna alkylating agents |
BR112017025778B1 (pt) * | 2015-11-16 | 2021-03-16 | Obi Pharma, Inc | composto, composição farmacêutica, método de tratar ou melhorar um ou mais sintomas de uma doença proliferativa em um indivíduo, método de inibir o crescimento de uma célula, processo de fabricação, e processo para resolução em um dos enantiômeros do racemato do composto |
CN109219610A (zh) * | 2016-04-04 | 2019-01-15 | 新泽西州立拉特格斯大学 | 拓扑异构酶毒物 |
BR112019013371A2 (pt) | 2017-01-06 | 2019-12-10 | Rivus Pharmaceuticals Inc | novos derivados de fenila |
RU2020126177A (ru) | 2018-01-09 | 2022-02-10 | Лиганд Фармасьютикалз, Инк. | Ацетальные соединения и их терапевтическое применение |
WO2019238886A1 (en) | 2018-06-13 | 2019-12-19 | University Of Dundee | Bifunctional molecules for targeting usp14 |
CN112585127A (zh) | 2018-06-13 | 2021-03-30 | 安菲斯塔治疗有限责任公司 | 用于靶向UchL5的双功能分子 |
JP2021527137A (ja) | 2018-06-13 | 2021-10-11 | アンフィスタ セラピューティクス リミテッド | Rpn11を標的化するための二機能性分子 |
CN110746459A (zh) * | 2018-07-24 | 2020-02-04 | 上海喀露蓝科技有限公司 | 一种艾伏磷酰胺的制备方法 |
EP3650046A1 (en) | 2018-11-08 | 2020-05-13 | Cellis AG | Mesenchymal stem cell based targeted active ingredient delivery system |
CN109705187B (zh) * | 2019-01-29 | 2021-08-20 | 石家庄学院 | 一种雷公藤红素衍生物及其制备方法与应用 |
CN112755001B (zh) * | 2019-11-01 | 2022-04-12 | 深圳艾欣达伟医药科技有限公司 | 口服给药的固体剂型药物 |
WO2021185986A1 (en) | 2020-03-18 | 2021-09-23 | Cellis Ag | Ferritin variants with increased stability, complexation ability and transferrin receptor affinity |
CA3212386A1 (en) | 2021-03-18 | 2022-09-22 | Alessandro ARCOVITO | Ferritin variants with increased stability and complexation ability |
KR20240047452A (ko) | 2021-08-27 | 2024-04-12 | 아센타위츠 파마슈티컬즈 리미티드 | 동결건조 제형 용액과 동결건조 제형, 및 이의 방법과 용도 |
KR20240051965A (ko) | 2021-08-27 | 2024-04-22 | 아센타위츠 파마슈티컬즈 리미티드 | Th-302를 이용한 parp 억제제에 내성이 있는 환자의 치료 |
WO2024056413A1 (en) | 2022-09-13 | 2024-03-21 | Cellis Ag | Isolated targeted delivery system for the treatment of glioma |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3652579A (en) | 1969-06-26 | 1972-03-28 | Hoffmann La Roche | 1-methyl-2-substituted 5-nitroimidazoles |
DE2229248C3 (de) | 1971-07-30 | 1980-03-27 | Gruppo Lepetit S.P.A., Mailand (Italien) | 5-Iminomethyl-2-nitroimidazoI-Derivate und Verfahren zu deren Herstellung |
US4921963A (en) | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
JPH0819111B2 (ja) | 1987-10-22 | 1996-02-28 | ポーラ化成工業株式会社 | 2―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤 |
US5190929A (en) | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
US4908356A (en) | 1988-05-25 | 1990-03-13 | Research Corporation Technologies, Inc. | Aldophosphamide derivatives useful as antitumor agents |
US5403932A (en) | 1988-05-25 | 1995-04-04 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
DE3835772A1 (de) | 1988-10-20 | 1990-04-26 | Deutsches Krebsforsch | Tumorhemmende saccharid-konjugate |
JP2626727B2 (ja) | 1990-01-26 | 1997-07-02 | ポーラ化成工業株式会社 | 2―ニトロイミダゾール誘導体、その製造法及びこれを有効成分とする放射線増感剤 |
HU9201539D0 (en) | 1990-09-11 | 1992-08-28 | Kortec Ag | Method and device for gasifying gasifiable materials and/or transforming gas as well as heat exchanger of high temperature for executing said method |
US5233031A (en) | 1991-09-23 | 1993-08-03 | University Of Rochester | Phosphoramidate analogs of 2'-deoxyuridine |
DE69233669T2 (de) | 1991-10-23 | 2007-10-25 | Cancer Research Technology Ltd. | Bakterielle nitroreduktase zur reduzierung von cb 1954 und analogen davon in eine zytotoxische form |
US5750782A (en) | 1992-11-27 | 1998-05-12 | Cancer Research Campaign Technology Limited | Nitroaniline derivatives and their use as anti-tumour agents |
US5306727A (en) | 1993-04-30 | 1994-04-26 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
EP0700376A4 (en) | 1993-05-25 | 1996-05-22 | Auckland Uniservices Ltd | NITROBENZILE MUSTARD QUARTERARY SALTS AND THEIR USE AS CYTOTOXIC AGENTS SELECTIVELY ACTING AGAINST HYPOXIA |
ES2148259T3 (es) | 1993-09-22 | 2000-10-16 | Hoechst Ag | Pro-profarmacos, su produccion y uso. |
JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
US5659061A (en) * | 1995-04-20 | 1997-08-19 | Drug Innovation & Design, Inc. | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities |
GB9516943D0 (en) | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
US6218519B1 (en) | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
US5728271A (en) | 1996-05-20 | 1998-03-17 | Rti Resource Transforms International Ltd. | Energy efficient liquefaction of biomaterials by thermolysis |
JP4371433B2 (ja) | 1996-05-20 | 2009-11-25 | ダイナモーティブ・エナジー・システムズ・コーポレイション | 熱分解によるバイオマテリアルのエネルギ効率的な液化 |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US6251933B1 (en) | 1996-12-13 | 2001-06-26 | The Cancer Research Campaign Technology Limited | Seco precursors of cyclopropylindolines and their use as prodrugs |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
US6017948A (en) | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
US7914994B2 (en) | 1998-12-24 | 2011-03-29 | Cepheid | Method for separating an analyte from a sample |
US6240925B1 (en) | 1999-03-23 | 2001-06-05 | Cynosure, Inc. | Photothermal vascular targeting with bioreductive agents |
GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
JP4629238B2 (ja) * | 1999-05-24 | 2011-02-09 | サザン・リサーチ・インスティテュート | イソホスホアミドマスタード・アナログ及びその使用 |
US6649193B1 (en) | 1999-06-11 | 2003-11-18 | Henceforth Hibernia Inc. | Prophylactic therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions |
AU5935600A (en) | 1999-07-14 | 2001-01-30 | Richard F. Borch | Phosphoramide compounds |
CA2397203A1 (en) | 2000-03-31 | 2001-10-11 | Sandra C. Tobias | Phosphoramidate prodrugs |
US20030091574A1 (en) | 2001-03-23 | 2003-05-15 | Gevas Philip C. | Combination treatment of pancreatic cancer |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US6506739B1 (en) | 2001-05-01 | 2003-01-14 | Telik, Inc. | Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents |
EP1434778A4 (en) | 2001-05-31 | 2005-07-13 | Medarex Inc | CYTOTOXINS, PROMEDICAMENTS, BINDERS AND STABILIZERS USEFUL THEREFOR |
FR2825926A1 (fr) | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
KR20030067275A (ko) | 2002-02-07 | 2003-08-14 | 주식회사 하이폭시 | 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제 |
US20040009667A1 (en) | 2002-02-07 | 2004-01-15 | Etsuo Iijima | Etching method |
JP4488351B2 (ja) | 2002-02-21 | 2010-06-23 | インスティトゥート オブ ヴァイロロジー | 可溶型の炭酸脱水酵素IX(s−CAIX)、s−CAIXを検出するためのアッセイ、CAIXとHER−2/neu/c−erbB−2の同時発現、非免疫優性エピトープに対するCAIX特異的モノクローナル抗体 |
JP4227771B2 (ja) | 2002-07-17 | 2009-02-18 | 三菱重工業株式会社 | バイオマスのガス化方法 |
US6833390B2 (en) | 2002-07-22 | 2004-12-21 | Bayer Polymers Llc | Process for preparing closed-cell water-blown rigid polyurethane foams having improved mechanical properties |
DE10237931A1 (de) | 2002-08-14 | 2004-02-26 | Endress + Hauser Gmbh + Co. Kg | Vorrichtung zur Überwachung eines vorbestimmten Füllstands eines Messmediums in einem Behälter |
JP3990718B2 (ja) | 2003-01-09 | 2007-10-17 | ファイザー・インク | キナーゼ阻害剤としてのジアゼピノインドール誘導体 |
GB0306908D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Bioreductively activated stilbene prodrugs |
GB0306907D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Boireductively-activated prodrugs |
ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
US6855695B2 (en) | 2003-06-13 | 2005-02-15 | Vion Pharmaceuticals, Inc. | Water-soluble SHPs as novel alkylating agents |
US7340059B2 (en) | 2003-06-17 | 2008-03-04 | Intel Corporation | Programmable scrambler and De-scrambler for digital telephony equipment |
JP2005041733A (ja) | 2003-07-28 | 2005-02-17 | National Institute Of Advanced Industrial & Technology | バイオマスによる水素製造法 |
KR101226631B1 (ko) | 2004-02-06 | 2013-01-28 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 항암 치료 방법 |
US7432106B2 (en) | 2004-03-24 | 2008-10-07 | Applied Biosystems Inc. | Liquid processing device including gas trap, and system and method |
AU2005241093B2 (en) | 2004-05-04 | 2008-06-05 | Institute Of Virology Of Slovak Academy Of Sciences | MN/CA IX/ CA9 and renal cancer prognosis |
IL162713A (en) | 2004-06-24 | 2011-04-28 | Desalitech Ltd | Apparatus and methods for continuous desalination in closed circuit without containers |
WO2006015263A2 (en) | 2004-07-29 | 2006-02-09 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
WO2006015191A2 (en) | 2004-07-29 | 2006-02-09 | Threshold Pharmaceuticals, Inc. | Multicyclic lonidamine analogs |
KR20070086595A (ko) | 2004-11-22 | 2007-08-27 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 튜불린 결합 항암제 및 이의 전구약물 |
US20070117784A1 (en) | 2005-03-04 | 2007-05-24 | Novacea, Inc. | Treatment of hyperproliferative diseases with anthraquinones |
PL1896040T3 (pl) | 2005-06-29 | 2012-12-31 | Threshold Pharmaceuticals Inc | Proleki alkilatora fosforoamidowego |
CA2624707A1 (en) | 2005-10-03 | 2007-04-12 | Genetix Pharmaceuticals, Inc. | Method for selectively depleting hypoxic cells |
WO2008011588A2 (en) | 2006-07-20 | 2008-01-24 | Threshold Pharmaceuticals, Inc. | Glycoconjugates of phosphoramidate alkylators for treatment of cancer |
WO2008033041A1 (en) | 2006-09-11 | 2008-03-20 | Auckland Uniservices Limited | Cancer treatment |
JP2008069017A (ja) | 2006-09-12 | 2008-03-27 | Matsushita Electric Ind Co Ltd | 水素製造方法 |
US7807454B2 (en) | 2006-10-18 | 2010-10-05 | The Regents Of The University Of California | Microfluidic magnetophoretic device and methods for using the same |
WO2008076826A1 (en) | 2006-12-13 | 2008-06-26 | Threshold Pharmaceuticals, Inc. | Pyrophosphoramide alkylators |
US8552048B2 (en) | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
JP5174411B2 (ja) | 2007-09-28 | 2013-04-03 | 独立行政法人石油天然ガス・金属鉱物資源機構 | 管式リフォーマーの有効熱利用方法 |
US8216607B2 (en) | 2008-03-17 | 2012-07-10 | Roger Williams Hospital | Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer |
US8591921B2 (en) | 2008-04-10 | 2013-11-26 | Virginia Commonwealth University | Induction of tumor hypoxia for cancer therapy |
EP2706059A1 (en) | 2008-06-11 | 2014-03-12 | Genentech, Inc. | Diazacarbazoles and methods of use |
JP4665021B2 (ja) | 2008-09-03 | 2011-04-06 | 三菱重工業株式会社 | バイオマスのガス化方法 |
US8946275B2 (en) | 2008-10-21 | 2015-02-03 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
WO2010108091A2 (en) | 2009-03-20 | 2010-09-23 | Pbs Biotech, Inc. | Automatable aseptic sample withdrawal system |
CA2760932A1 (en) | 2009-05-04 | 2010-11-11 | Thierry Nivaggioli | Mtor pathway inhibitors for treating ocular disorders |
US20110135739A1 (en) | 2009-11-06 | 2011-06-09 | Bennett Carter | Oral Formulations of a Hedgehog Pathway Inhibitor |
JP5659536B2 (ja) | 2010-03-31 | 2015-01-28 | 新日鐵住金株式会社 | タール含有ガスの改質用触媒及びその製造方法、並びにタール含有ガスの改質方法 |
WO2012006032A2 (en) | 2010-06-28 | 2012-01-12 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
US20140010805A1 (en) | 2010-07-12 | 2014-01-09 | Karen Curd | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
EP2593796A4 (en) | 2010-07-16 | 2016-07-27 | Auckland Uniservices Ltd | BACTERIAL NITROREDUCTASE ENZYMES AND ASSOCIATED METHODS |
KR20140038390A (ko) | 2011-04-01 | 2014-03-28 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
JP2014510795A (ja) | 2011-04-15 | 2014-05-01 | スレッショルド ファーマシューティカルズ、インク. | 経口投与用の単位用量形態物 |
JP5805989B2 (ja) | 2011-04-26 | 2015-11-10 | 大塚電子株式会社 | 電気泳動移動度測定用セル並びにそれを用いた測定装置及び測定方法 |
CN104159845A (zh) | 2011-12-20 | 2014-11-19 | 学校法人长崎综合科学大学 | 合成气体的生成方法以及制造装置和液体燃料的合成方法以及合成装置 |
EP2793899A4 (en) | 2011-12-22 | 2015-06-17 | Threshold Pharmaceuticals Inc | HYPOXIA ACTIVATED DRUGS AND MTOR INHIBITORS FOR TREATING CANCER |
JP2015511226A (ja) | 2012-01-31 | 2015-04-16 | スレッショルド ファーマシューティカルズ,インコーポレイテッド | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
-
2006
- 2006-06-29 PL PL06786161T patent/PL1896040T3/pl unknown
- 2006-06-29 KR KR1020087002436A patent/KR101198571B1/ko active IP Right Grant
- 2006-06-29 ZA ZA200800314A patent/ZA200800314B/xx unknown
- 2006-06-29 CN CN201210251557.3A patent/CN102746336B/zh active Active
- 2006-06-29 RS RS20120449A patent/RS52505B/en unknown
- 2006-06-29 BR BRPI0612845A patent/BRPI0612845A8/pt active Search and Examination
- 2006-06-29 NZ NZ565378A patent/NZ565378A/en not_active IP Right Cessation
- 2006-06-29 EP EP06786161A patent/EP1896040B1/en active Active
- 2006-06-29 WO PCT/US2006/025881 patent/WO2007002931A2/en active Application Filing
- 2006-06-29 ES ES11157963.7T patent/ES2579235T3/es active Active
- 2006-06-29 ES ES06786161T patent/ES2389532T3/es active Active
- 2006-06-29 AU AU2006263433A patent/AU2006263433B8/en active Active
- 2006-06-29 PT PT06786161T patent/PT1896040E/pt unknown
- 2006-06-29 JP JP2008519666A patent/JP5180824B2/ja active Active
- 2006-06-29 TW TW095123590A patent/TWI384989B/zh active
- 2006-06-29 DK DK06786161.7T patent/DK1896040T3/da active
- 2006-06-29 CN CN2006800300828A patent/CN101501054B/zh active Active
- 2006-06-29 EP EP11157963.7A patent/EP2336141B1/en active Active
- 2006-06-29 US US11/993,822 patent/US8003625B2/en active Active
- 2006-06-29 CA CA2613312A patent/CA2613312C/en active Active
- 2006-06-29 RU RU2008103195/04A patent/RU2414475C2/ru not_active IP Right Cessation
- 2006-06-29 SI SI200631455T patent/SI1896040T1/sl unknown
-
2007
- 2007-12-19 IL IL188236A patent/IL188236A/en active IP Right Grant
-
2008
- 2008-01-23 NO NO20080442A patent/NO334420B1/no not_active IP Right Cessation
- 2008-08-26 HK HK08109465.9A patent/HK1113754A1/xx unknown
-
2011
- 2011-05-05 AU AU2011202075A patent/AU2011202075B8/en active Active
- 2011-06-17 US US13/163,303 patent/US8507464B2/en active Active
-
2012
- 2012-05-16 JP JP2012112647A patent/JP5781007B2/ja active Active
- 2012-10-05 HR HRP20120803TT patent/HRP20120803T1/hr unknown
- 2012-10-23 CY CY20121100999T patent/CY1113250T1/el unknown
-
2013
- 2013-07-12 US US13/941,261 patent/US8664204B2/en active Active
- 2013-12-10 US US14/102,213 patent/US9226932B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012153722A5 (ja) | ||
JP2019501204A5 (ja) | ||
JP2016501221A5 (ja) | ||
JP2017525730A5 (ja) | ||
JP2013522292A5 (ja) | ||
JP2015078199A5 (ja) | ||
JP2020514311A5 (ja) | ||
JP2015533176A5 (ja) | ||
JP2013544846A5 (ja) | ||
JP2009514881A5 (ja) | ||
JP2016526540A5 (ja) | ||
NZ628078A (en) | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
JP2016504365A5 (ja) | ||
JP2016503414A5 (ja) | ||
JP2017530171A5 (ja) | ||
JP2013535491A5 (ja) | ||
JP2016525135A5 (ja) | ||
JP2015512398A5 (ja) | ||
JP2017511321A5 (ja) | ||
JP2019516766A5 (ja) | ||
JP2022071077A5 (ja) | ||
JP2017526662A5 (ja) | ||
JP2017507175A5 (ja) | ||
JP2016512831A5 (ja) | ||
JP2019533651A5 (ja) |